In 2016, an Ontario family impacted by PKD for generations got together with their friends to bike the Bruce Trail in an effort to raise money for PKD research. They travelled 480 km and raised over $11,000. This year, Bike to the Moon participants across Canada travelled over 4,000 km...
Each year, Health Canada recognizes September 4th as National PKD Awareness Day! This year we are looking for volunteers who want to help spread awareness in their own communities by working with us to secure local proclamations.
Join us for the 2018 Walk to END PKD, the PKD Foundation of Canada's signature fundraising campaign!
On November 25, 2017 we held our biennial Canadian PKD Symposium, which included participants from the PKD medical community and various renal healthcare centres, as well as PKD patients, their families and loved ones.
On Monday, April 9, the PKD Foundation of Canada attended the Can-SOLVE CKD SPOR Initiative reception where we were awarded the Pewter Upper Canada Medal by the Toronto General & Western Hospital Foundation for our support of Dr. York Pei’s Hereditary Kidney Disease Clinic at Toronto General Hospital.
We wish to share this prestigious honour with every volunteer and donor who has joined in the fight to end PKD, furthered our mission and helped to advance critical Canadian research of PKD.
History of the medal: The Upper Canada Medal was originally created by the Loyal and Patriotic Society of Upper Canada to provide recognition of distinguished service and bravery to volunteer soldiers in the War of 1812.
Recognizing an even greater need, the Loyal and Patriotic Society decided to reduce the medals to gold bullion for the establishment, in 1829, of the original Toronto General Hospital.
Toronto General & Western Hospital Foundations continue to honour both the original intent of the medals - to recognize distinguished service - and their later role - to support the greater good.
Many thanks to the Toronto General & Western Hospital Foundation for this recognition.
The FDA Approves JYNARQUE™ as the First Treatment in the United States for Adult Patients with ADPKD
We’re excited to announce that on Tuesday, April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (pronounced jin-AR-kew and also known as tolvaptan) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD).
Kidney Month is recognized in March across Canada and the United States. We spend this time raising awareness of the importance of our kidneys to our overall health, and to reduce the frequency and impact kidney disease and its associated health problems have on an international level. We encourage you all to get out there and share your PKD journey with as many people as possible!
Submitted by Chiara Gamberi, Ph. D.
Affiliate Assistant Professor, Department of Biology, Concordia University
Season's greetings to you and yours from the PKD Foundation of Canada!
We are pleased to share some encouraging news regarding the treatment landscape for those living with ADPKD. Today, Otsuka announced results from their Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). This data was presented at the American Society of Nephrology (ASN) Conference in New Orleans and published online in the New England Journal of Medicine.